AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.

Presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, data also include week-28 findings from a phototherapy substudy, in which treatment groups receiving RINVOQ plus whole-body narrowband ultraviolet B (NB-UVB) phototherapy showed numerically higher repigmentation responses than groups receiving RINVOQ alone.